11 completed, 8 terminated, 3 withdrawn. 16 Phase 2, 4 Phase 1, 2 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 9, Terminated 6, Withdrawn 1 |
| Phase 1 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
| Not applicable | 2 | Terminated 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Stage IIIC Melanoma: new trials by email Literature Review of Stage IIIC Melanoma trials Research Report on Stage IIIC Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma LN-144, Cyclophosphamide, Mesna - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 | Withdrawn | James Isaacs, MD | 2024-12-02 | 2025-06-05 | |
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations trametinib, laboratory biomarker analysis, pharmacological study - Recurrent Melanoma, Stage IIIB Melanoma | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 9 | 2015-01-01 | 2021-05-28 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery aldesleukin, ipilimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | CINJRegulatory | 9 | 2014-11-26 | 2023-07-18 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | Yale University | 49 | 2014-05-01 | 2020-01-02 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2013-05-01 | 2014-09-25 |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery dabrafenib, trametinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced) | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 13 | 2013-01-01 | 2017-06-23 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis - Recurrent Melanoma, Stage IIA Melanoma | Early Phase 1 | Completed | Mayo Clinic | 30 | 2012-10-01 | 2018-10-09 |
| FDG-PET in Advanced Melanoma [18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography - Recurrent Melanoma, Stage IIIA Melanoma | Not applicable | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2012-05-01 | 2017-04-13 |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma isolated limb perfusion, melphalan, quality-of-life assessment - Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin | Not applicable | Withdrawn | Albert Einstein College of Medicine | 2012-04-01 | 2015-07-23 | |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2012-01-01 | 2014-06-18 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery axitinib, laboratory biomarker analysis - Extraocular Extension Melanoma, Metastatic Intraocular Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 25 | 2012-01-01 | 2018-05-09 |
| Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma therapeutic conventional surgery, laboratory biomarker analysis, Axitinib - Melanoma, Malignant Melanoma | Phase 2 | Completed | University of California, Irvine | 11 | 2011-12-01 | 2021-01-20 |
| Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays - Recurrent Melanoma, Stage IIIc Melanoma | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2011-10-01 | 2016-05-30 |
| RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery gamma-secretase/Notch signalling pathway inhibitor RO4929097, pharmacological study, therapeutic conventional surgery - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-09-01 | 2013-01-31 | |
| Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Denileukin diftitox - Stage IIIC Melanoma, Stage IV Melanoma | Phase 2 | Completed | Eisai Inc. | 75 | 2010-06-22 | 2022-04-13 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery imatinib mesylate, laboratory biomarker analysis - Acral Lentiginous Malignant Melanoma, Recurrent Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2007-04-01 | 2014-12-23 |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma dasatinib - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2006-12-01 | 2014-05-15 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
Showing 20 of 22. Sign in to see all of them.
Melanoma (22) · Uveal Melanoma (3) · Carcinoma, Basal Cell (1) · Carcinoma, Renal Cell (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1) · Skin Neoplasms (1)
Neoplasms by Histologic Type (22) · Neoplasms by Site (22) · Neoplasms, Germ Cell and Embryonal (22) · Neoplasms, Nerve Tissue (22) · Neuroectodermal Tumors (22) · Neuroendocrine Tumors (22) · Nevi and Melanomas (22) · Skin Diseases (22) · Skin and Connective Tissue Diseases (22) · Neoplasms (21) · Skin Neoplasms (21) · Eye Diseases (3) · Eye Neoplasms (3) · Uveal Diseases (3) · Uveal Neoplasms (3)
montanide ISA 51 (3) · Axitinib (2) · Immunohistochemistry (2) · Interleukin-2 (2) · MART-1 Antigen (2) · aldesleukin (2) · incomplete Freund's adjuvant (2) · trametinib (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · AZD 6244 (1) · Biopsy (1) · CTLA-4 Antigen (1) · Coal Tar (1) · Cyclophosphamide (1) · Dasatinib (1)
National Cancer Institute (NCI) (8) · Vanderbilt-Ingram Cancer Center (4) · Albert Einstein College of Medicine (1) · CINJRegulatory (1) · Eisai Inc. (1) · James Isaacs, MD (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · University of California, Irvine (1) · University of Southern California (1) · Wake Forest University Health Sciences (1) · Yale University (1)
United States (21)
Jeffrey Weber (2) · Anna Pavlick (1) · Douglas Johnson (1) · Frank Hodi (1) · Harriet Kluger (1) · Howard Kaufman (1) · James Isaacs, MD (1) · Jason Luke (1) · Jeffrey Sosman (1) · Jeffrey Sosman, MD (1) · John P. Fruehauf, MD, PhD (1) · Katia Papalezova (1) · Mark Kelley (1) · Matuesz Opyrchal, MD (1) · Patricia LoRusso, D.O. (1)
PMID 21642685, PMID 25797743, PMID 31998643, PMID 33861486
N01CM62204 (2), P30CA006516 (2), P30CA068485 (2), U01CA062490 (2), N01CM00100 (1), N01CM62206 (1), P30CA008748 (1), P30CA012197 (1), P30CA013330 (1), P30CA016056 (1), P30CA016359 (1), P30CA022453 (1), P30CA072720 (1), R21CA082614 (1), UM1CA186709 (1)